In contrast, the prolonged in vitro treatment of ovarian cancer cells with thymoquinone did not result in NFκB activation, suggesting that there are specific factors within the TME which support the activation of NFκB in TAMs, in vivo [50]. This evidence concerns the gene NFKB1 and ovarian cancer.